U.S. FDA approves Pfizer's nasal spray for migraine
Send a link to a friend
[March 10, 2023]
(Reuters) -The U.S. Food and Drug Administration (FDA) on Friday
approved Pfizer Inc's nasal spray for migraine, giving patients access
to a potentially fast-acting option to treat their headaches.
The drug Zavzpret, also known as zavegepant, was approved for the
treatment of acute migraine with or without aura in adults, the company
said.
Pfizer added Zavzpret and a host of other migraine treatments, including
Nurtec ODT, to it drugs portfolio through its $11.6 billion buyout of
Biohaven Pharmaceutical last year.
Zavzpret belongs to a class of drugs called calcitonin gene-related
peptide (CGRP) inhibitors and will compete with other therapies from
AbbVie Inc, Eli Lilly and Co, Amgen Inc and Teva Pharmaceutical.
Pfizer is hoping to gain a competitive edge with zavegepant's quicker
speed of action than other migraine treatments. Biohaven has pitched it
as the "Epipen of migraine".
[to top of second column]
|
![](../images/031023PIX/health65.jpg)
Pfizer logo is seen in this illustration
taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration/
![](http://archives.lincolndailynews.com/2023/Mar/10/images/ads/current/heartland_lda_020123.png) The approval is based on data from a
late-stage study that showed the drug helped in relieving migraine
pain in less than 15 minutes.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Devika
Syamnath and Anil D'Silva)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |